---
title: CDMO Daily News — August 15, 2026
slug: daily-news-2026-08-15-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: August 15 CDMO daily: Cabaletta Bio Adds ElevateBio as Second CDMO Partner Alongside Lonza for Rese-cel; NurExone Selects Made Scientific for Exclusive U.S.…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-15-cdmo
published_at: 2026-08-15T00:00:15.744Z
last_updated: 2026-08-15T00:04:13.952Z
---

### Cabaletta Bio Adds [ElevateBio](/companies/elevate) as Second CDMO Partner Alongside [Lonza](/companies/lonza) for Rese-cel
- Cabaletta Bio expanded its CAR T manufacturing network by adding [ElevateBio](/companies/elevate) as a CDMO partner alongside [Lonza](/companies/lonza) to increase capacity and supply-chain resilience ahead of rese-cel commercialization.
- The company remains on track to report RESET-Myositis registrational data in mid-2027 and plans BLA submission in H2 2027, supported by automated manufacturing partnerships with ElevateBio, Lonza, and [Cellares](/companies/cellares).

**Operational Impact**

[ElevateBio](/companies/elevate) and [Lonza](/companies/lonza) now share commercial manufacturing responsibility for a late-stage CAR T program, signaling demand for dual-CDMO capacity in autologous [cell therapies](/companies/celltherapies) and validating automated manufacturing platforms for clinical-to-commercial transition.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cabaletta-bio-selects-elevatebio-as-second-cdmo-for-rese-cel-manufacturing)*

---

### NurExone Selects [Made Scientific](/companies/madescientific) for Exclusive U.S. Exosome GMP Manufacturing
- NurExone and subsidiary Exo-Top signed binding MOU with [Made Scientific](/companies/madescientific) for exclusive U.S. GMP manufacturing and aseptic fill-finish of bone marrow-derived exosomes.
- Made Scientific will begin technology transfer immediately, targeting first GMP batches in H1 2027 from its 60,000-sq-ft FDA- and EU GMP Annex 1-compliant Princeton, New Jersey facility.
- Five-year initial term with renewal options; partnership supports NurExone's clinical pipeline and commercial exosome product strategy.

**Operational Impact**

[Made Scientific](/companies/madescientific)'s Princeton facility gains exclusive exosome manufacturing and fill-finish capacity for NurExone's clinical and commercial pipeline, anchoring utilization through 2027 and beyond.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/nurexone-signs-exclusive-u-s-gmp-manufacturing-partnership-with-made-scientific)*

---

### [Samsung Biologics](/companies/samsungbiologics) Achieves 90-Day Dual-Site Tech Transfer for GMP Biologics Manufacturing
- [Samsung Biologics](/companies/samsungbiologics) demonstrated a parallel, risk-based tech-transfer model delivering first GMP batch at second facility within 90 days by parallelizing gap assessment, analytical readiness, and supply chain qualification from day one.
- Centralized analytical platforms and cookie-cutter facility design across five plants enable single unified process control strategy, eliminating site-to-site method transfer delays and reducing validation studies per site.
- Case studies show comparable cell culture profiles and product titers across 10,000-liter and 15,000-liter bioreactors; Samsung executing five dual-site transfers simultaneously in 2026 with target to improve beyond 90-day timeline.

**Operational Impact**

Samsung's parallel tech-transfer framework and unified process control strategy across five standardized plants materially reduce timelines and validation costs for sponsors hedging commercial supply risk through dual-site manufacturing.

*Source: [PharmaSource RSS](https://pharmasource.global/content/podcast/how-to-complete-a-dual-site-biologics-tech-transfer-in-90-days)*

## References

1. [PharmaSource RSS — Cabaletta Bio Adds ElevateBio as Second CDMO Partner Alongside Lonza for Rese-cel](https://pharmasource.global/content/news/cdmo-news/cabaletta-bio-selects-elevatebio-as-second-cdmo-for-rese-cel-manufacturing)
2. [PharmaSource RSS — NurExone Selects Made Scientific for Exclusive U.S. Exosome GMP Manufacturing](https://pharmasource.global/content/news/cdmo-news/nurexone-signs-exclusive-u-s-gmp-manufacturing-partnership-with-made-scientific)
3. [PharmaSource RSS — Samsung Biologics Achieves 90-Day Dual-Site Tech Transfer for GMP Biologics Manufacturing](https://pharmasource.global/content/podcast/how-to-complete-a-dual-site-biologics-tech-transfer-in-90-days)

Source: https://www.cdmo.directory/posts/daily-news-2026-08-15-cdmo